Long-acting Beta Agonist Step Down Study
Information source: Johns Hopkins University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: Fluticasone/Salmeterol Diskus (Drug); Fluticasone/Salmeterol Diskus (Drug); Fluticasone Diskus (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Johns Hopkins University Official(s) and/or principal investigator(s): Robert A Wise, MD, Study Director, Affiliation: Johns Hopkins University Linda Rogers, MD, Principal Investigator, Affiliation: New York University School of Medicine
Summary
This study is a 56-week, multi-center, blinded, randomized, double-masked parallel group
comparative effectiveness study of approaches to stepping down therapy for patients with
well-controlled asthma treated with combination ICS and LABA.
Clinical Details
Official title: Long-acting Beta Agonist Step Down Study
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Treatment Failure
Secondary outcome: Pulmonary FunctionRate of episodes of poor asthma control
Detailed description:
Current asthma guidelines recommend stepping down therapy once asthma is controlled for at
least 3 months. For patients treated with inhaled corticosteroids (ICS) alone, a dose
reduction of 25-50% to a minimal dose that controls disease is recommended. The optimal
approach to reducing treatment in patients with asthma treated with combination inhaled
corticosteroids and long-acting beta agonists (ICS/LABA) is not clear. The American Lung
Association Asthma Clinical Research Center (ALAACRC) is a network of 18 asthma research
centers with the goal of performing clinical trials directly relevant to clinical practice.
The question of the optimal way to de-escalate therapy in patients with asthma that is well
controlled on fixed dose combination ICS/LABA is a key question for practitioners caring for
patients with moderate to severe persistent asthma. We propose a 56 week multi-center,
prospective, randomized, three-arm parallel group comparative effectiveness study comparing
three approaches to care of patients with asthma well-controlled for three months on
combination ICS/LABA: reduction of ICS dose and maintenance of LABA, initial discontinuation
of LABA with continuation of ICS, and continuation of stable dose ICS/LABA. Our primary
goal is to perform a pragmatic study that resembles clinical practice and determine the
optimal treatment strategy that results in the lowest rate of treatment failure over 48
weeks of follow-up. Additional exploratory analyses include assessing risk factors for
step-down failure, and to assess the duration of time that asthma control is maintained when
therapy is de-escalated.
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- age 12-80 years
- physician diagnosed asthma that is well-controlled on moderate dose ICS/LABA
based on an Asthma Control Test (ACT) score more than or equal to 20, and the absence
of unscheduled visits or use of rescue prednisone for 4 weeks prior to enrollment
- pre-bronchodilator FEV1 more than or equal to 70% predicted
Exclusion Criteria:
- chronic oral steroid therapy
- hospitalization or urgent care visit within 4 weeks of the screening visit
- lung disease other than asthma including COPD, bronchiectasis, sarcoidosis or other
lung disease
- less than 10 pack/yr of tobacco use and abstinence for at least 1 yr
- history of extensive environmental tobacco exposure or occupational exposure
suggestive of possible COPD per judgment of investigator
- post bronchodilator FEV1 less than 70% predicted
- near fatal asthma (intubation or ICU admission for asthma) within 2 yrs of enrollment
- high risk of near fatal or fatal asthma
- history of known premature birth less than 33 weeks or any significant level of
respiratory care including prolonged oxygen administration or mechanical ventilation
during the neonatal period
- unstable cardiac disease (decompensated CHF, unstable angina, recent MI, atrial
fibrillation, supraventricular or ventricular tachycardia, congenital heart disease,
or severe uncontrolled hypertension)
- other major chronic illnesses which in the judgment of the study physician would
interfere with participation in the study e. g. including but not limited to
uncontrolled diabetes, uncontrolled HIV infection or other immune system disorder
- drug allergies to any component of study drug or history of adverse reaction to short
or long acting beta agonists
- for women of child bearing potential; not pregnant, not lactating and agree to
practice an adequate birth control method (abstinence, combination barrier and
spermicide, or hormonal) for the duration of the study
Locations and Contacts
University of Arizona, Arizona Respiratory Center, Tucson, Arizona 85724, United States
University of California, San Diego, San Diego, California 92103, United States
National Jewish Health, Denver, Colorado 80206, United States
Nemours Children's Clinic, Jacksonville, Florida 32207, United States
University of Miami/University of South Florida, Tampa, Florida 33613, United States
The Illinois Consortium, Chicago, Illinois 60611, United States
St. Vincent Healthcare, Indianapolis, Indiana 46260, United States
St. Vincent Hospital and Health Care Center, Inc, Indianapolis, Indiana 46290, United States
Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center, New Orleans, Louisiana 70112, United States
University of Missouri, Kansas City School of Medicine, Kansas City, Missouri 64108, United States
Washington University/St. Louis University, St. Louis, Missouri 63110, United States
Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York 11040, United States
New York University School of Medicine, New York, New York 10016, United States
Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College, Valhalla, New York 10595, United States
Duke University Medical Center, Durham, North Carolina 27710, United States
The Ohio State University Medical Center, Columbus, Ohio 43221, United States
Baylor College of Medicine, Houston, Texas 77030, United States
Northern New England Consortium, Colchester, Vermont 05446, United States
University of Virginia, Charlottesville, Virginia 22908, United States
Additional Information
American Lung Association
Starting date: March 2012
Last updated: January 27, 2015
|